Efficacy and safety of repaglinide on glycemic control in diabetic patients with chronic renal failure [Diamond study-2]

Efficacy and safety of repaglinide on glycemic control in diabetic patients with chronic renal failure [Diamond study-2] - Efficacy of repaglinide in diabetic patients with chronic renal failure [Diamond study-2]

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009166

Enrollment

Registered

2012-10-23

Start date

2012-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with chronic renal failure

Interventions

repaglinide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the following requirements [both 1) and 2)] 1) Patients with chronic renal failure who have serum creatinine >= 1.5mg/dL or eGFR < 60mL/min/1.73m2 (except patients on dialysis) 2) Patients with type 2 diabetes mellitus who have HbA1c (NGSP) >= 6.5% and <= 10.0% or glycated albumin >= 18.0% and <= 30.0%

Exclusion criteria

Exclusion criteria: Patients with severe liver dysfunction (AST >= 100 IU/L or ALT >= 100 IU/L) Patients with malignancy under medical treatment Patients with untreated diabetic retinopathy Patients disqualified by doctor for any reason

Design outcomes

Primary

Measure	Time frame
Change from baseline to week 12 in HbA1c	—

Secondary

Measure	Time frame
Change from baseline to week 12 in glycated albumin	—

Countries

Japan

Contacts

Public ContactKatsuhito Mori

Osaka City University Graduate School of Medicine 2nd department of internal medicine

ktmori@med-osaka-cu.ac.jp06-6645-3806

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026